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Type 2 diabetes mellitus (T2DM) is one of the risk factors for Parkinson's disease (PD). 
Insulin desensitisation has been observed in the brains of patients, which may promote 
neurodegeneration. Incretins are a family of growth factors that can re-sensitise insulin 
signalling. We have previously shown that mimetics of glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP) have neuroprotective effects in the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP) mouse model of PD. Recently, dual 
GLP-1/GIP receptor agonists have been developed. We therefore tested the novel dual 
agonist DA3-CH in comparison with the best GLP-1 analogue currently on the market, 
liraglutide (both drugs 25nmol/kg ip once-daily for 7 days) in the MPTP mouse model of PD 
(25mg/kg ip once-daily for 7 days). In the Rotarod and grip strength assessment, DA3-CH 
was superior to liraglutide in reversing the MPTP–induced motor impairment. Dopamine 
synthesis as indicated by levels of tyrosine hydroxylase was much reduced by MPTP in the 
substantia nigra and striatum, and DA3-CH reversed this while liragutide only partially 
reversed this. The chronic inflammation response as shown in increased levels of activated 
microglia and astrocytes was reduced by both drugs. Importantly, expression levels of the 
neuroprotective growth factor Glial Derived Neurotrophic Factor (GDNF) was much 
enhanced by both DA3-CH and liragutide. The results demonstrate that the combination of 
GLP-1 and GIP receptor activation is superior to single GLP-1 receptor activation alone. 
Therefore, new dual agonists may be a promising treatment for PD. The GLP-1 receptor 







Parkinson disease (PD) is a neurodegenerative chronic disorder. Because of the increase in 
life expectancy in the industrialised nations, patient numbers are on the increase (Schapira, 
2013). PD is diagnosed by characteristic motor impairments (Langston, 2002), caused by a 
reduction in striatal dopamine levels, which is due to the loss of dopaminergic neurons in the 
substantia nigra (Moore et al., 2005; Wakamatsu et al., 2008). Importantly, type 2 diabetes 
(T2DM) has been identified as a risk factor for PD (Hu et al., 2007; Schernhammer et al., 
2011; Sun et al., 2012; Wahlqvist et al., 2012). Insulin signaling in the brain plays an 
important role in neuronal metabolism, repair, and synaptic efficacy (Freiherr et al., 2013; 
Ghasemi et al., 2013; van der Heide et al., 2006). Insulin desensitisation has been observed in 
the brains of patients with PD (Aviles-Olmos et al., 2013b; Moroo et al., 1994; Morris et al., 
2011). Protease-resistant analogues of incretin hormones have been developed to treat T2DM 
(Campbell and Drucker, 2013; Holst, 2004). The incretin hormones are glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (Baggio and 
Drucker, 2007; Campbell and Drucker, 2013; Doyle and Egan, 2003). Mimetics of GLP-1 
and GIP have shown neuroprotective effects in animal models of Alzheimer’s disease 
(Bomfim et al., 2012; Duffy and Holscher, 2013; Faivre and Holscher, 2013a, b; Li et al., 
2010; McClean et al., 2011) and were found to re-sensitise insulin signaling in the brain 
(Long-Smith et al., 2013). GLP-1 receptor agonists also have neuroprotective effects in 
animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et al., 
2015a; Zhang et al., 2015). The GLP-1 mimetic exendin-4 showed protective effects in a 
pilot clinical study in PD patients (Aviles-Olmos et al., 2013a; Aviles-Olmos et al., 2014). 
We previously tested GLP-1 or GIP analogues in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropypridine (MPTP) mouse model of PD, demonstrating that both incretin signaling 
		 4	
pathways protect the brain from the MPTP induced pathology such as motor impairment, 
increase of a-synuclein levels, chronic inflammation in the brain, loss of dopaminergic 
neurons, oxidative stress and growth factor expression (Ji et al., 2016a; Li et al., 2016; Liu et 
al., 2015a; Liu et al., 2015b; Zhang et al., 2015). 
Recently, dual GLP-1/GIP receptor agonist peptides have been developed as a treatment of 
T2DM. These dual receptor agonists show superior effects to single GLP-1 analogues such as 
liraglutide (Finan et al., 2013). We tested a novel dual agonist (DA-JC1) in rotenone stressed 
SH-SY5Y cells and demonstrated that it was cytoprotective at much lower doses than single 
GLP-1 or GIP receptor agonists (Jalewa et al., 2016). We furthermore tested DA-JC1 in the 
MPTP mouse model of PD, which showed some protective effect but which was not superior 
to liraglutide (Cao et al., 2016; Ji et al., 2016b). On the basis of this, we tested the novel 
GLP-1/GIP dual agonist DA3-CH and compared it to the currently most effective GLP-1 
analogue liraglutide on the market (Lovshin and Drucker, 2009) in the MPTP mouse model 
of PD to investigate if this dual receptor agonist is more effective in protecting the brain than 





2.1 Animals and drug treatment 
Eight weeks old adult male C57BL/6 mice (15-20g) were obtained from the Academy of 
Military Medical Sciences (AMMS China). The animals were maintained under 12h 
light/dark cycles, at 22 ± 3°C and 50-55% humidity with food and water ad libitum. All 
animal procedures were licensed by the Shanxi Medical University ethics committee and 
performed in accordance to National Institute of Health (NIH) guideline (NIH publication 
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NO. 85-23. Revised 1985). Mice were randomly divided into four groups: 1) control (saline 
treated) group, 2) MPTP only treated group (once daily 25mg/kg ip. for 7 days), 3) MPTP 
(once daily 25mg/kg ip. for 7 days) followed immediately by liraglutide treated group 
(25nmol/kg ip. once daily), and 4) the MPTP (once daily 25mg/kg ip. for 7 days) followed 
immediately by DA3-CH (25nmol/kg ip. once daily) treated group. N=10 per group. The 
experiment lasted 7 days. A timeline is shown in fig. 1. 
	
2.2 Peptides 
The dual agonist DA3-CH and liraglutide (Peptide Purity: 95.77%) were obtained from 
Chinapeptides Ltd (Shanghai, China). The purity of the peptide was confirmed by reversed-
phase HPLC and characterised using matrix assisted laser desorption/ionisation time of flight 
(MALDI-TOF) mass spectrometry.  
 
Peptide sequence for GLP-1 (human) 
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 
 
Peptide sequence for GIP (human) 
YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-NH2 
 
Peptide sequence of the GLP-1/GIP dual agonist DA3-CH (Finan et al., 2013): 
YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSK-NH2 
 





Blood plasma glucose levels were tested two h after injection on the first and last day. The 
Sannuo rapid detection blood glucose meter, product number 1304110 (Sinocare Inc. in 
Changsha, China) was used to test blood sampled from the tail vein. Levels are reported as 
mmol/l. 
 
2.4 Motor activity tests 
RotaRod test 
Motor coordination was evaluated on a RotaRod (YLS-4C, Academy of medical sciences in 
Shandong, China) consisted of a five-lane rotating rod (diameter 7.5 cm) designed for mice. 
Animals were tested with a few runs to familiarize the animals to the procedure. Animals 
were positioned on a rotating rod accelerating from 5 rpm-20 rpm (14,000 g) over a 180 s 
time period. Mice that completed the task received a final latency time of 180 s. The length of 
time the mouse was able to stay on the rotating rod was recorded. 
 
Grip strength test 
Muscle grip strength was assessed 4 h after MPTP injection by a grip test as previously 
published (Luo et al., 2011). The mouse was placed onto a horizontal wire, which the mouse 
gripped by its front paws. The mice were scored 3 for gripping the wire with both paws, 2 for 
gripping the wire with one paw, and 1 for not gripping the wire with either paw. The test was 
repeated three times for each mouse on day 1 and on day 7 of the experiment. 
 
2.5 Immunohistochemistry  
Anesthetized mice were transcardially perfused with cold paraformaldehyde 4 %. The brain 
was isolated and fixed in 4%PFA. Then the brains were embedded in paraffin. Coronal 
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sections were cut at a 5-μm thickness with a microtome (Leica, Germany). Sections were	
incubated	with	primary	Ab	for	2h	at	37°C:	anti-TH	1:200	(Abcam, Cambridge, UK), GFAP 
1:500 (Abcam, Cambridge, UK), Iba1 1:4000 (Abcam, Cambridge, UK), anti-GDNF 1:100 
(Abcam, Cambridge, UK), Sections were then incubated with secondary Ab biotin-
conjugated goat anti- mouse (KPL) for 30min at 37°. Staining was visualized using a solution 
of 0.05 % 3,3’-diaminobenzidine (DAB), 50 mM Tris–HCl pH 7.2, 0.02 % H2O2. Images 
were captured with an Olympus BX51 microscope. Microglial and astroglia cells were 
analysed with ImageJ program in a double- blind design. The images were analysed for 
staining intensity which represents the level of target protein present. Four sections were 
randomly chosen through the midbrain, with a total of 12 sections per individual animal using 
unbiased stereological rules. The striatum and the substantia nigra was analysed as shown in 
the sample images. All analysis was done blind to treatment. 
 
2.6 Western blots 
At the end of a week, animals were anesthetised with pentobarbital (40 mg/kg body weight), 
and cardiac perfusion was carried out using 0.01 M phosphate-buffered saline (PBS) at pH 
7.4 to wash out the blood. The brains were snap frozen and stored at -8 0 °C for further use. 
The midbrain and striatum regions were dissected out from one hemisphere. Protein extracts 
were prepared from the ventral midbrain regions and homogenized in an ice cold RIPA 
buffer (containing1% deoxycholate,1% Triton X-100,0.1%SDS) and phenyl-methylsulfonyl 
fluoride (PMSF). Homogenates were then centrifuged at 12,000rpm, at 4 °C for 10 min, and 
the supernatant was collected for analysis. Protein concentration was determined by BCA 
Protein Assay Kit. Samples were then added with loading buffer to the same concentration, 
boiled, cooled and centrifuged. Upon use, SDS (12%) was added to the homogenate. 
Approximately 10-30 μg of protein was run on a Tris–HCl gel (Bio-Rad, Richmond, USA) 
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which was run at 80V for 30 min, and 120V for 1h, and transferred to a PVDF membranes 
(Bio-Rad, Richmond, USA) at 100-120mA for 40 min. Membranes were blocked in 5% milk 
for 2 h at room temperature. Primary antibodies, which were incubated overnight at 4 °C, 
were: anti-Iba1 1:1000 (Abcam, UK), anti-GFAP (glial fibrillary acidic protein) 1:10000 
(Abcam, Cambridge, UK), anti-GDNF 1:500 (Abcam, Cambridge, UK), β-actin 1:3000. 
Secondary antibodies used anti-rabbit IgG peroxidase conjugated (Boster, China) at 1:3000 to 
1:5000 concentrations respectively, and incubated at room temperature for 1 h. Before this, 
PVDF membranes were washed three times in TBST for 10 min. Blots were visualized with 
Molecular Imager ChemiDoc™ XRS+ (Bio-Rad, Richmond, USA). Optical density 
measurements were taken by Image Lab™ Software version 2.0. 
 
2.7 Statistical analysis 
All data were displayed as means standard, error bars represent S.E.M.. Data were analysed 
using the statistical package Prism (Graphpad software, USA). Repeated measures analysis of 
variance using a one-way or two-way ANOVA were used, followed by Tukey’s multiple 
comparison test for post-hoc comparison.  Probability value less than 0.05 was considered to 







































































































The data presented here demonstrate that both the GLP-1 analogue liraglutide and the novel 
GLP-1/GIP dual receptor agonist DA3-CH have neuroprotective properties in the MPTP 
mouse model of PD. MPTP is lipophilic and can cross the blood–brain barrier (BBB). In 
neurons, MPTP is metabolised into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by 
monoamine oxidase B (Glover et al., 1986). MPP+ has been shown to kill primarily 
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dopamine-producing neurons in the substantia nigra (Nakamura and Vincent, 1986). MPP+ 
blocks complex 1 in the mitochondrial electron transport chain, which leads to the production 
of free radicals and to cell death (Kinemuchi et al., 1987; Smith and Bennett, 1997).  
Liraglutide and DA3-CH have been developed as treatments for type 2 diabetes (Finan et al., 
2013; Lovshin and Drucker, 2009). Importantly, as shown previously, GLP-1 analogues do 
not greatly affect blood plasma glucose levels or body weight in non-diabetic or non-obese 
animals or humans (Faivre et al., 2012; Gallwitz, 2006; George et al., 2014). We were able to 
show that neither liraglutide nor DA3-CH had prominent effects on body weight or blood 
glucose levels. In the motor tasks, both drugs were able to counteract the detrimental effects 
of MPTP on motor coordination and grip strength. DA3-CH was significantly more effective 
than liraglutide. MPTP causes a decrease of protein synthesis of key enzymes such as 
tyrosine hydroxylase (TH), an enzyme that is required for dopamine synthesis. Both drugs 
were able to protect dopaminergic neurons to some degree, with DA3-CH again being more 
effective than liraglutide. It is of interest to note that grip strength was very much impaired 
on day 1 after MPTP treatment, in contrast to rotarod performance. This result is in line with 
previous results using these techniques (Cao et al., 2016). This difference demonstrates that 
the toxin affects muscle strength to a much higher degree than sensorimotor coordination as 
measured in the rotarod. Chronic inflammation is a key aspect of PD, and the activation of 
microglia and astrocytes lead to release of pro-inflammatory cytokines, enhanced oxidative 
stress, synaptic failure, reduced energy utilisation and mitochondrial damage (Moran and 
Graeber, 2008; Tansey and Goldberg, 2010). Both drugs tested reduced the activation of 
microglia and astrocytes by MPTP, which may be an important part in the neuroprotective 
properties of these incretin analogues. Glial-derive neurotropic factor (GDNF) is a key 
growth factor that is important for the differentiation and function of dopaminergic neurons. 
Its role in neuronal metabolism and its neuroprotective profile has been well established 
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(Airaksinen and Saarma, 2002; Broome et al., 1999; Drinkut et al., 2012; Kordower and 
Bjorklund, 2013; Moran and Graeber, 2008). Long-lasting analogues of GDNF are currently 
under investigation as a potential treatment of PD (see eg. NCT01621581), but as GDNF 
cannot cross the blood-brain barrier (BBB) (Allen et al., 2013), no effective treatment has 
been developed yet. GLP-1 and GIP are members of the growth factor family (Holscher, 
2014). We have previously shown that GLP-1 or GIP analogues enhance the expression of 
Brain-Derived Neurotrophic Factor (BDNF) (Ji et al., 2016b; Li et al., 2017), a growth factor 
that protects synaptic activity from stressors (Nagahara et al., 2009). GLP-1 and GIP can 
cross the BBB (Dogrukol-Ak et al., 2004; Hunter and Holscher, 2012; Kastin et al., 2002) 
and enhance the expression of key growth factors such as BDNF or GDNF. Therefore, the 
increase of the expression of these neuroprotective growth factors by incretin analogues may 
explain some of the neuroprotective effects that we and others have shown. In our study, the 
dual receptor agonist was more potent than the single GLP-1 receptor agonist in upregulating 
GDNF expression. The slight discrepancy between the results obtained using the histology 
and the western blot method can be explained by the different sensitivity in detecting the 
target. The western blot analysis is the more accurate technique in quantifying protein levels.  
Previously we tested GLP-1 or GIP receptor agonists in the MPTP mouse model of PD. We 
found that the second generation GLP-1 mimetics liraglutide and lixisenatide were more 
effective than the first generation drug exendin-4. Motor coordination and activity was 
improved by the newer GLP-1 mimetics, and the expression of TH was also rescued by both 
drugs. Importantly, levels of the pro-apoptotic signal BAX were reduced, the cell survival 
signal Bcl-2 was increased by both drugs (Liu et al., 2015a). Similar protective effects were 
observed with the GLP-1 analogue (Val8)GLP-1-Glu-PAL (Zhang et al., 2015). We also 
tested a protease-resistant analogue of GIP, D-Ala2-GIP-glu-PAL, in the acute MPTP mouse 
model of PD. This GIP analogue also reduced the effects of MPTP on motor activity and 
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coordination, and TH levels in the substantia nigra and striatum were enhanced. MPTP 
treatment reduced synapse numbers in the striatum, and the GIP analogue reversed this to 
some degree. Importantly, the cAMP/PKA/CREB growth factor second messenger signalling 
pathway was activated by this drug (Li et al., 2016). In a chronic MPTP study, we observed 
further neuroprotective effects induced by this GIP analogue. Moreover, MPTP treatment 
increased the levels of alpha-synuclein in the brain, and D-Ala2-GIP-glu-PAL reduced these 
levels to almost normal values. D-Ala2-GIP-glu-PAL also reduced the chronic inflammation 
response in the brain, reduced oxidative stress and lipid peroxidation, and increased the 
expression of Brain Derived Neurotrophic Factor (BDNF) (Li et al., 2017).  
Based on our findings, novel dual GLP-1/GIP receptor agonists are a promising new strategy 
that may show improved neuroprotective effects than single GLP-1 or GIP analogues. Such 
novel dual agonists have already shown superior effects in preclinical and clinical trials in 
diabetes. compared to lirglutide (Finan et al., 2013). One of these dual agonists that we 
named DA-JC1 reduced the MPTP-induced impairment of motor control, increased the level 
of TH positive neurons in the substantia nigra, reduced the activation of microglia and 
astrocytes, enhanced growth factor cell signalling such as Pi3k activity and Bcl-2 and BDNF 
levels, while reducing pro- apoptotic BAX signalling (Cao et al., 2016; Ji et al., 2016b). We 
also tested DA-JC1 in the 6-OHDA rat model of PD where it displayed good neuroprotective 
effects and enhanced dopamine levels in the striatum (Jalewa et al., 2017). However, the 
effects were not superior to liraglutide, and higher doses were required to see the effects 
previously demonstrated with single GLP-1 analogues. We therefore tested the novel DA3-
CH dual agonist in direct comparison with liraglutide and show here for the first time that 
this dual agonist not only shows good neuroprotective effects in the MPTP mouse model of 
PD, but that it is superior to liraglutide. DA-JC1 differs from the DA3-CH dual agonist 
mainly in the addition of a C16 fatty acid that enhances the survival time in the blood stream 
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but reduces BBB permeability. 
Based on the extensive preclinical data, clinical trials have started that investigate the 
neuroprotective effects of exendin-4 (Byetta, Bydureon®) and liraglutide (Victoza®), drugs 
that are already on the market as T2DM treatments, in PD patients. A pilot trial of exendin-4 
in PD patients has already shown good effects (NCT01174810). This pilot study tested the 
effects of exendin-4 in 45 patients. There were clear improvements in the motor coordination 
as assessed in the MDS-UPDRS tests, and cognition was improved as measured by the Mattis 
DRS-2 test battery that had been designed to evaluate cognitive impairments in PD patients 
(Aviles-Olmos et al., 2013a). Patients were re-tested 12 months later, and the differences in 
motor performance and cognitive scores was still visible (Aviles-Olmos et al., 2014). This 
test was important as the pilot study was an open label trial. The fact that the drug 
improvement was still observed 12 months after the trial had stopped suggests that the 
difference in performance is not due to a placebo effect. A phase II double-blind, placebo 
controlled clinical trial that tested the once-weekly formulation of exendin-4, Bydureon®, 
has been completed (NCT01971242), but the results have not been published at the time of 
writing. A phase II trial testing liraglutide in PD patients has started in Sept. 2016, testing 
patients in a double blind, placebo controlled trial for one year (NCT02953665). A further 
clinical trial testing the GLP-1 receptor agonist Lixisenatide in PD patients is in planning. 
As clinical trials of novel dual GLP-1/GIP analogues in diabetes patients are ongoing, it is 
highly likely that several of these will be brought to the market. Once these drugs are 
licenced for use in patients, they can be fast-tracked into clinical trials in PD patients 
(Hölscher, 2016).  
Conclusion: The data that we present here demonstrate that novel dual GLP-1/GIP receptor 
agonists such as DA3-CH can show superior neuroprotective effects compared to single 
GLP-1 receptor agonists, and hold promise to be developed as a drug treatment that is 
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Rotarod: summary of all days















A Rotarod results for each day










































































TH levels in the substantia nigra














TH levels in the striatum
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Fig.	7:	Expression	of	Glia-Derived	Neurotrophic	Factor	(GDNF)	in	the	cortex.	A	one-way	
ANOVA	found	an	overall	difference,	a	post-hoc	test	found	differences	Between	groups:	
***=P<0.001	compared	to	controls;	$$$	=P<0.001	compared	to	DA3+MPTP	group;	£££	
=P<0.001	compared	to	Liraglutide	+MPTP	group.	Shown	are	sample	micrographs.	A	=	
control;	B	=	Liraglutide	+MPTP;	C	=	DA3+MPTP;	D	=	MPTP	only.	Scale	bar	=	20µm.	
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Fig.	8:	Western	blot	analysis	of	protein	levels	of	GDNF	(A)	and	the	inflammation	markers	
GFAP	(B)	and	IBA-1	(C).	A	one-way	ANOVA	found	an	overall	difference	and	post-hoc	tests	
showed	group	differences:	*=P<0.05,	**=P<0.01,	***=P<0.01	compared	to	controls.	
$$=P<0.01,	$$$=P<0.01	compared	to	the	MPTP	group.	££=P<0.01	comparing	the	liraglutide	
+MPTP	group	with	the	DA3+MPTP	group.	(D)	Shown	are	sample	western	blots.	
	
